Drugs.com - Clinical Trials

New Data on Investigational Therapy Doxecitine and Doxribtimine for Thymidine Kinase 2 Deficiency Presented at Muscular Dystrophy Association (MDA) 2025 Conference

Brussels (Belgium) 19 March 2025 – UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living with...

Mar 19, 2025 - 22:31
 0
New Data on Investigational Therapy Doxecitine and Doxribtimine for Thymidine Kinase 2 Deficiency Presented at Muscular Dystrophy Association (MDA) 2025 Conference
Brussels (Belgium) 19 March 2025 – UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living with...
Read More

Tags:

Previous Article

Wendy’s Fuels Fans With $1 March Madness Jr. Bacon Cheeseburger or Double Stack

Next Article

Two new projects aim to boost downtown San Jose in unexpected ways using AI

Related Posts

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics Announces FDA Fast Track and Enrollment U...

Feb 27, 2025  0

Amgen and Kyowa Kirin Provide Top-Line Results from Rocatinlimab Phase 3 Ignite Study in Adults with Moderate to Severe Atopic Dermatitis

Amgen and Kyowa Kirin Provide Top-Line Results from Roc...

Mar 9, 2025  0

BlueRock Therapeutics Receives FDA Fast Track Designation for OpCT-001 for the Treatment of Primary Photoreceptor Diseases

BlueRock Therapeutics Receives FDA Fast Track Designati...

Mar 1, 2025  0